ESTRUMATE VETERINARY

Land: Israel

Sprache: Englisch

Quelle: Ministry of Health

Wirkstoff:

CLOPROSTENOL AS SODIUM

Verfügbar ab:

INTERVET ( ISRAEL) LTD

Darreichungsform:

SOLUTION FOR INJECTION

Zusammensetzung:

CLOPROSTENOL AS SODIUM 0.250 MG/ML

Verabreichungsweg:

I.M

Verschreibungstyp:

Required

Hergestellt von:

VET PHARMA FRIESOYTHE GMBH, GERMANY

Anwendungsgebiete:

Estrumate is a potent luteolytic agent. It causes functional and morphological regression of the corpus luteum ( luteolysis) in cattle and horses followed by return to oestrus and normal ovulation.

Berechtigungsdatum:

2021-01-31

Gebrauchsinformation

CONSUMER PACKAGE INSERT FOR A VETERINARY MEDICINAL
PRODUCT
THE MEDICINE IS DISPENSED WITH A VETERINARIAN’S PRESCRIPTION ONLY
FOR USE IN ANIMALS ONLY
1.
NAME OF THE MEDICINAL PRODUCT AND DOSAGE FORM:
ESTRUMATE VETERINARY
Solution for Injection
2.
COMPOSITION:
Each 1 ml comprises:
Active ingredient:
Cloprostenol sodium 0.263 mg
(equivalent to 0.250 mg cloprostenol)
Preservative:
Benzyl alcohol 20 mg
A list of inactive ingredients is detailed in section 13 –
“Further information”.
3.
WHAT IS THE MEDICINAL PRODUCT INTENDED FOR:
Estrumate Veterinary is a solution with potent luteolytic
characteristics,
causing morphological and functional regression of the corpus luteum
in
cattle and horses, followed by return to oestrus and normal ovulation.
THERAPEUTIC GROUP: Synthetic prostaglandin.
Estrumate Veterinary is a synthetic prostaglandin intended for use in
cattle
and horses. It is similar in structure to prostaglandin F2 alpha (PGF
2
alpha).
4.
CONTRAINDICATIONS:
Do not administer Estrumate Veterinary to pregnant animals unless the
objective is to terminate pregnancy.
5.
SIDE EFFECTS:
In very rare cases (less than one animal in 10,000 animals, including
isolated reports), anaphylactic-type reactions can be observed which
require immediate medical care.
On rare occasions (more than one animal but less than 10 in 10,000
animals),
severe
life-threatening
local
bacterial
infections
may
occur
associated with clostridial proliferation at the injection site. It is
important to
keep treated animals under observation and, if such infection occurs
aggressive
antibiotic
therapy,
particularly
covering
clostridial
species,
should be employed as a matter of urgency.
Careful aseptic techniques should be employed to decrease the
possibility
of these infections.
If you notice any serious side effects or other effects not mentioned
in this
consumer leaflet, please inform your veterinarian.
Side effects can be reported to the Ministry of Health by clicking on
the link
“Reporting side effects due to drug treatment” found on the